Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Warrant (NQ:NAMSW)

8.780 -0.800 (-8.35%)
Streaming Delayed Price Updated: 3:51 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,842
Open 9.040
Bid (Size) 7.270 (2)
Ask (Size) 12.34 (1)
Prev. Close 9.580
Today's Range 8.780 - 9.560
52wk Range 5.450 - 16.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
From NewAmsterdam Pharma N.V.
Via GlobeNewswire

Performance

YTD
-39.0%
-39.0%
1 Month
+1.6%
+1.6%
3 Month
-28.3%
-28.3%
6 Month
+18.5%
+18.5%
1 Year
+9.6%
+9.6%

More News

Read More
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
From NewAmsterdam Pharma N.V.
Via GlobeNewswire

Frequently Asked Questions

Is NewAmsterdam Pharma Company N.V. - Warrant publicly traded?
Yes, NewAmsterdam Pharma Company N.V. - Warrant is publicly traded.
What exchange does NewAmsterdam Pharma Company N.V. - Warrant trade on?
NewAmsterdam Pharma Company N.V. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for NewAmsterdam Pharma Company N.V. - Warrant?
The ticker symbol for NewAmsterdam Pharma Company N.V. - Warrant is NAMSW on the Nasdaq Stock Market
What is the current price of NewAmsterdam Pharma Company N.V. - Warrant?
The current price of NewAmsterdam Pharma Company N.V. - Warrant is 8.780
When was NewAmsterdam Pharma Company N.V. - Warrant last traded?
The last trade of NewAmsterdam Pharma Company N.V. - Warrant was at 06/06/25 03:51 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.